Many investors appear to be quite bearish on Dendreon Corporation (DNDN), especially if you look at the percentage of the float that is sold short for this stock. Currently, 26.92% of the float is ...

On Thursday, Dendreon Corporation (NASDAQ:DNDN) will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they’ll do ...

What’s a smart Dendreon Corporation (NASDAQ:DNDN) investor to do? To the average investor, there are tons of methods shareholders can use to monitor the equity markets. Two of the most under-the-radar ...

Many investors appear to be quite bearish on Dendreon Corporation (DNDN), especially if you look at the percentage of the float that is sold short for this stock. Currently, 26.96% of the float is ...

Mitchell Gold, the CEO of cancer drugmaker Dendreon (DNDN), sold $34 million of the company's stock prior to announcing in August that he would not be able to meet his revenue guidance for the year, a ...

Mitchell Gold, President and CEO of Dendreon Corporation (DNDN), will visit NASDAQ MarketSite in Times Square and preside over the NASDAQ Opening Bell. The Opening Bell is available from 9:20 a.m. to ...

The reimbursement decision is a big deal because most prostate cancer patients are over 65, and hence covered by Medicare, and allowing off-label use could really open up the market for the ...

Dendreon's (DNDN) drug Provenge used to treat advanced prostate cancer may work better than its competitors over a period of time. It is not easy to measure efficacy between immunological drugs and ...